You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Article metrics

Article menu

Download PDFPDF

XML
Oncolytic and local immunotherapy
Original research
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

 

Online download statistics by month:

Online download statistics by month: April 2020 to May 2023

AbstractFullPdf
Apr 202017017162
May 2020550550233
Jun 202022822959
Jul 202015815848
Aug 202015415153
Sep 202019519559
Oct 202015015059
Nov 202011111151
Dec 202016116162
Jan 202112612643
Feb 202115815851
Mar 202114514552
Apr 202116916956
May 2021858548
Jun 2021848448
Jul 2021686835
Aug 2021848448
Sep 202110610658
Oct 2021787851
Nov 2021878939
Dec 2021525238
Jan 2022798335
Feb 2022707238
Mar 2022758051
Apr 2022657334
May 2022848856
Jun 2022687137
Jul 20228810042
Aug 2022687245
Sep 2022636524
Oct 2022646635
Nov 2022737836
Dec 202211211425
Jan 2023585842
Feb 2023686828
Mar 2023616227
Apr 2023333326
May 2023363723
Total428443401857